<SEC-DOCUMENT>0001144204-18-034349.txt : 20180731
<SEC-HEADER>0001144204-18-034349.hdr.sgml : 20180731
<ACCEPTANCE-DATETIME>20180615105555
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-18-034349
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20180615

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 66%; text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 17%; font-size: 10pt; font-weight: bold">New York<BR>
Northern California<BR>
Washington DC<BR>
S&atilde;o Paulo<BR>
London</TD>
    <TD STYLE="width: 17%; font-size: 10pt; font-weight: bold">Paris<BR>
Madrid<BR>
Tokyo<BR>
Beijing<BR>
Hong Kong</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sophia Hudson</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Davis Polk &amp; Wardwell LLP</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">450 Lexington Avenue</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10017</FONT></TD>
    <TD STYLE="width: 40%; padding-left: 6.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212 450 4762 tel</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212 701 5800 fax</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">sophia.hudson@davispolk.com</P></TD>
    <TD STYLE="width: 31%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">June 15, 2018</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-bottom: 13pt; font-size: 10pt"><B>Re:</B></TD>
    <TD STYLE="width: 95%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Entera Bio Ltd.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Amendment No. 4 to Registration Statement on Form F-1</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Submitted May 17, 2018</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0"><B>CIK No. 0001638097</B>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">CONFIDENTIAL</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms. Ada D. Sarmento and Ms. Mary B. Breslin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance<BR>
U.S. Securities and Exchange Commission<BR>
100 F Street, N.E.<BR>
Washington, DC 20549-3628</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Ms. Sarmento and Ms. Breslin,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On behalf of our client, Entera Bio Ltd., a company incorporated
in Israel with limited liability (the &ldquo;<B>Company</B>&rdquo;), we are responding to the comments from the Staff (the &ldquo;<B>Staff</B>&rdquo;)
of the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) relating to Amendment No. 4 to the Company&rsquo;s
Registration Statement on Form F-1 (the &ldquo;<B>Registration Statement</B>&rdquo;) contained in the Staff&rsquo;s letter dated
June 11, 2018 (the &ldquo;<B>Comment Letter</B>&rdquo;). In response to the comments set forth in the Comment Letter, the Company
has revised the Registration Statement and is filing an amended Registration Statement (&ldquo;<B>Amendment No. 5</B>&rdquo;) together
with this response letter. The amended Registration Statement also contains certain additional updates and revisions. We are also
sending, under separate cover, a copy of Amendment No. 5 (including newly-filed exhibits) and three marked copies of the Registration
Statement showing the changes to the Registration Statement publicly filed on May 17, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Set forth below are the Company&rsquo;s responses to the Staff&rsquo;s
comments in the Comment Letter. The responses and information below are based on information provided to us by the Company. For
convenience, the Staff&rsquo;s comments are repeated below, followed by the Company&rsquo;s response to the comments as well as
a summary of the responsive actions taken. We have included page numbers to refer to the location in Amendment No. 5 where the
revised language addressing a particular comment appears.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; padding-right: 0; padding-left: 0; font-size: 10pt">Ms. Ada D. Sarmento,<BR>
Ms. Mary B. Breslin<BR>
Division of Corporation Finance<BR>
U.S. Securities and Exchange Commission</TD>
    <TD STYLE="vertical-align: bottom; width: 33%; padding-right: 0; padding-left: 0; text-align: center; font-size: 10pt">2</TD>
    <TD STYLE="vertical-align: bottom; width: 33%; padding-right: 0; padding-left: 0; text-align: right; font-size: 10pt">June 15, 2018</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Draft Amendment No. 4 to Registration Statement on Form F-1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Use of Proceeds, page 9, 10 and 56</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">We note your revised disclosure that you will need to
raise additional capital for the Phase 2b/3 trial of EB612 and for the Phase 2a trial for EB613. Please further revise to describe
how far in the clinical development, and specifically these trials, you expect to reach with the proceeds from this offering.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>Response:</B></TD><TD>In response to the Staff&rsquo;s comment, we have revised the disclosure on pages 9, 10 and 56 of the Registration Statement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please do not hesitate to contact me at (212) 450-4762, (212)
701-5800 (fax) or sophia.hudson@davispolk.com or Michael Kaplan at (212) 450-4111, (212) 701-5800 (fax) or michael.kaplan@davispolk.com
if you have any questions regarding the foregoing or if I can provide any additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,<BR>
<BR>
/s/ Sophia Hudson<BR>
<BR>
Sophia Hudson</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 0; padding-left: 0; font-size: 10pt">cc:</TD>
    <TD STYLE="width: 92%; padding-right: 0; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Via E-mail</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Phillip Schwartz, Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mira Rosenzweig, Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Entera Bio Ltd.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael Kaplan, Davis Polk</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ivan Blumenthal, Mintz Levin</P></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  E ,(# 2(  A$! Q$!_\0
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M-+&*,G@&6,Y(7_:!./2ON^UN8KRWBG@D6:"5!)')&=RNI&001U!%?EK^WO\
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M$Z=U,Z<$=B#D$'H16,<!5P^(IQK1]UM>:9O+,J.*PU66'E:44_)K0XO]F/\
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M>/@&;XA?M 2^)M04SQ:%#)J$LC#[UU*2%/UR7;\*X;]JC_D[KQ?_ -ARW_\
M:=?<'_!.7X;_ /"'_ D:]/%LOO$MTUYDCGR$^2(?HQ_X%7P_^U1_R=UXN_[#
M=O\ ^TZVP]?VV85;;1C9?)_YF&)P_P!7RRCS;RE=_/\ X![A_P %!/V>_&&L
M^-[7Q]HFE7.NZ+<:;#;726,9DEM7C!&2@Y*D'J.AS7/?"_\ X*,>*OA]X?L/
M"_BGPK9Z]:6,"VBON:TN3$J[0K*P*DX&.@S7I7[6'[5'Q?\ @'\4HM+TP::O
MA:\M8;G39+FQW&50H$J;\_># _@0:[77/VG?V:_BOX!-[XOBTZ:ZDM\SZ;=:
M>3>I)MY5&"YSGH0WI7%%S>&IQKT?:1Z..Z/0G&E'%59X>O[.?52V9B_LGZY^
MSGX[\?VM[X0\,2>$O'MJ)+B"SO97W,&4B3RCN*N,,<CJ!VKH_P#@IC_R;S;?
M]ANU_D]?$_[)7AVZ\4?M3>$_^$<MKA;*QU-M0.XY:WLT+']XWNI"^Y-?;'_!
M3+_DWBV_[#5K_)ZBO15',:*4F[VW=VC3#XB6(RJLY12M?963\SX&^"=O\6IY
MM7_X55_;OF@1_P!H?V(P4XYV;_UQ^-=U??L\_M'_ !AU6UA\0Z/X@U!D.([C
M7[L+##GJ>3@?@,U[5_P2LS_:_P 1AV\NS_\ :E?H56N.S.>%Q,H0@KKKUV.?
M+<HAC,)"<ZDK/I?3<_,/]HSX)M^RW^S/HWA@7JWVM^+-92?6[R$$(ZPQEHX$
MSSL4G//4\U[/_P $QOA_I=I\,]:\8-;12ZS?ZC)9BY907CAC"X13V!))..O%
M>@_M[_!W4?BQ\$7ET6W>\UC0;D:E#:QC+S1A2LJ*.[;3D#OMKY2_8=_:ZT+X
M&Z;J_A;Q>MS%HEU<_;+6^MXC(;>4@*Z.G4 X!R.A!S6:E5QN72Y-9WU_K^MC
M64*.7YI#VFE/EM'LCWG_ (*9> =*U#X/V'BW[-%'K6EZA# MTJ@.\,N59">X
MS@CTQ7S1\-O$EWJ'["'Q8T6:1GM=+UBSDMU)X02NA8#VRI/XUT_[<'[87A[X
MU^'M.\(^#OM$VCQ7*WE[J%Q$8_-=00D:*>2,G))]@*T+?X/:E\+?^">OBZ^U
MJVDLM5\1WMK?M:RC#Q0B5%B##L2,MCMNK?#QE0PE*G7TDYJR?JO^"<^)G#$8
MVM5P^L5!W:VV,O\ 8:_Y)9\>?^P'_P"TIJ^9/AM\2==^%M[=:GX=N%LM2N].
MDT\76W+PI(!N:/T? P#VS7TY^PS_ ,DM^//_ &!/_:4U<1_P3Y\,:5XH_:*T
M>+5["'4(;73I[N&.X7<BS*%VOCH2,G&:]%SC3GB9S5TK:?(\N-.=6G@Z=.5F
M[Z]M2S^P/;^!M3^/5K#XS@-WJ<J&31&NF#0&\!+'S ?O2$<KGN#WQ7ZT5^2_
M[:?P+NO@%\88]<T 266@ZS.=0TRXAR/LERK!GB![%6PR^Q]J^_\ ]D_]H"W_
M &@/A;:ZE,R1^(]/VVFK6R\8E XD _NN/F'XCM7@9M3]O&&-IN\6ON_K\SZ7
M):GU:<\!55IIW]?Z_(]JHHHKY@^N/GZ;]@_X)7$TDK^#E+R,78_;9^23D_Q^
MII%_8+^""L#_ ,(8IQV-Y.1_Z'1179]<Q/\ S\?WLXOJ.%W]E'[D>H?#WX/>
M"OA7;O%X3\-:?H8D&))+6$"1_P#><_,?Q-;WB3PUI7C#0[O1];T^WU32[Q#'
M/:72!XY%/8@T45S2G*4N9O4ZHTX1CR):=CY[D_X)V_!674#<C1=0CC+;OLJ:
ME*(1[8SG'XUV.N?L>?"#Q!HND:3<^"[..PTKS/LL=L[PD%\;BS*P+DX'+$T4
M5T/&8B5FZCT\V<L<%AHII4UKY(]#^'OP]T+X6^%;3PWX;M&L-'M"QAMS*TFS
M<Q8@%B3C)->;>+OV,OA#XZ\2:EKVL>$TN=4U&4S7,RW,T8=R.6VJP )]A116
M4:]6$G.,FF]]3:6'I5(J$X)I;*QZYX>T&P\*Z%I^CZ5;+9Z;8PK;V]NF<1QJ
M,*/R%>4>+/V/OA/XV\87OBC6?# N];O)UN9[G[5,NZ1<8. V!]T=J**4*U2F
MW*$FFQRHTZB49Q32\CT#QW\,_"WQ,\/_ -B>*-$M-:TT<K#=)NV$# 96ZJ?<
M&O"YO^"<_P %IKSSAI6J1)G/D1ZG)Y?TYYQ^-%%:4\36HJU.;2]3.KA:%9WJ
MP3?FCV7X7_!?P7\&]-DLO!^@6NCQS8,TL8+2S8Z;Y&RS?B:G^*'PH\+_ !C\
M.)H7BW3?[4TM9UN1#YKQ_O%SM.5(/<T45E[6?/[3F?-WZFOLJ?)[/E7+VZ&3
M\*/V?O GP1GU.7P;H@TF340@N6$\DF\)G;]YCC&3TKT:BBE.<JDN:;NRH4X4
MHJ,%9>05X?\ $C]C'X2_%'5I=5U7PTMGJ<QW37>ES-:O*?5@ORD^Y&:**JG5
MJ47S4Y-/R(JT:=:/+4BFO,C^'?[%7PC^&>K0ZIIWAD7VHP-NAN=5F:Z,3=BH
M;Y0??%>G_$'X>Z#\4_"MWX<\36/]HZ/=%6EM_,9-Q5@R\J0>H%%%5*O5J24Y
M2;:ZW)AAZ-.#IP@E%]+'(^!?V9OAS\-=)\0:;X>\/BPL]>@^S:A']HE?SH\$
M8RS''#'IZU6^&?[*OPR^$/B:/Q!X4\.#3-5C@:W6?[3+)B-L;AAF(["BBF\1
M6=[S>N^N_J)8:A'EM!:;:;>AUWQ,^%7A;XP>'!H?BW2H]6TT3+.L;LRE)%Z,
MK*00>3T/>N<^%O[-/P^^#.MW.J^#]%?2+RYA\B9ENY761,Y *LQ!P>AHHJ%6
<J1@Z:D^7M?0N5"E*:J.*YEUMJ>HT445D;'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
